Trial reportAmerican journal of respiratory and critical care medicine2025
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in
Abstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review.Pulmonary circulation · 2026Review
- Pulmonary arterial hypertension with signs of venous/capillary involvement in connective tissue diseases: paradigms and paradoxes.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Clinical research on pulmonary hypertension from a 2025 perspective: a narrative review.Journal of thoracic disease · 2026Review
- Identification of drug candidates for rescue of SOX17 gene targets in pulmonary arterial hypertension.bioRxiv : the preprint server for biology · 2026Article
- Hypoxic Pulmonary Hypertension: Molecular Mechanisms and Clinical Research Advances.International journal of molecular sciences · 2026Review
- NF-κB signaling as a critical inflammatory node in pulmonary arterial hypertension: from vascular remodeling to right heart failure.Frontiers in immunology · 2026Review
- Pulmonary veno-occlusive disease: Insights from animal models.Vascular pharmacology · 2025Review
- Sotatercept in pulmonary arterial hypertension: revolution, risk and the road ahead.The European respiratory journal · 2025Article
- Simplifying Sotatercept in Pulmonary Arterial Hypertension: Genetic Context Meets Treatment Response.American journal of respiratory and critical care medicine · 2025Article
- Sudden cardiac death in congenital heart disease-a narrative review and update.Frontiers in cardiovascular medicine · 2025Review
- Advances in diagnosis and patient profiling in pulmonary arterial hypertension for precision medicine.Therapeutic advances in respiratory diseaseReview
Corrections and comments
- Commented on by
Authors and funding
19 authors.
David MontaniUniversité Paris-Saclay, INSERM Unité Mixte de Recherche en Santé 999, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique (HPPIT), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre (Assistance Publique-Hôpitaux de Paris), European Reference Network for Rare Respiratory Diseases (ERN-LUNG), Le Kremlin-Bicêtre, France.ORCID 0000-0002-9358-6922
Vallerie V McLaughlinDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-8907-1651
J Simon R GibbsNational Heart and Lung Institute, Imperial College London, London, United Kingdom.ORCID 0000-0001-6147-9252
Mardi Gomberg-MaitlandDivision of Cardiology, Department of Medicine, George Washington University, Washington, District of Columbia.ORCID 0000-0003-0482-4560
Marius M HoeperDepartment of Respiratory Medicine and Infectious Diseases, Hannover Medical School and German Center for Lung Research, Hannover, Germany.ORCID 0000-0001-9086-2293
Ioana R PrestonLahey Hospital and Medical Center, Burlington, Massachusetts.ORCID 0000-0002-1378-7362
Rogerio SouzaPulmonary Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0003-2789-9143
Aaron B WaxmanDivision of Pulmonary Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0001-7797-0361
Pilar Escribano SubiasDepartment of Cardiology, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Instituto de Investigación del Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain.ORCID 0000-0002-6640-4839
Jeremy FeldmanBMC/Summit, Bend, Oregon.
Gisela M MeyerIrmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil.ORCID 0009-0009-7384-2595
Karen M OlssonDepartment of Respiratory Medicine and Infectious Diseases, Hannover Medical School and German Center for Lung Research, Hannover, Germany.ORCID 0000-0002-5302-1548
Florence CouletGenetics Department, Pitié-Salpêtrière Hospital, Sorbonne Universitè, Paris, France.ORCID 0000-0002-5325-5272
Solaiappan ManimaranMRL, Merck & Company, Inc., Rahway, New Jersey; and.ORCID 0000-0001-8485-780X
Yujie ZhaoMRL, Merck & Company, Inc., Rahway, New Jersey; and.ORCID 0000-0003-2896-4955
Anna LauMRL, Merck & Company, Inc., Rahway, New Jersey; and.ORCID 0000-0002-1546-7004
Janethe de Oliveira PenaMRL, Merck & Company, Inc., Rahway, New Jersey; and.ORCID 0009-0002-8735-4698
David B BadeschUniversity of Colorado, Denver, Colorado.
Marc HumbertUniversité Paris-Saclay, INSERM Unité Mixte de Recherche en Santé 999, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique (HPPIT), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre (Assistance Publique-Hôpitaux de Paris), European Reference Network for Rare Respiratory Diseases (ERN-LUNG), Le Kremlin-Bicêtre, France.ORCID 0000-0003-0703-2892
Funding
Merck
Abstract
PubMed holds no abstract for this paper.
Indexed as
Bone Morphogenetic Protein Receptors, Type IIHypertension, PulmonaryPulmonary Arterial HypertensionRecombinant Fusion ProteinsAdultDouble-Blind MethodFemaleHeterozygoteHumansMaleMiddle AgedMutationTreatment OutcomeBMPR2 protein, humanBone Morphogenetic Protein Receptors, Type IIRecombinant Fusion Proteinsgenetic variantheritable pulmonary arterial hypertensionpulmonary arterial hypertensionsotatercepttreatment outcome
Identifiers
PMID
40035659What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.